Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers.
- DOI
- 10.1016/j.phrs.2026.108471
- Published
- 2026 Sep 18
- Container
- Pharmacological research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.phrs.2026.108471,
title = {Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers.},
author = {Zhou M and Huo J and Wang W and Lai E and Han B and Zhang T},
year = {2026},
journal = {Pharmacological research},
doi = {10.1016/j.phrs.2026.108471},
url = {https://doi.org/10.1016/j.phrs.2026.108471}
}RIS
TY - JOUR TI - Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers. AU - Zhou M AU - Huo J AU - Wang W AU - Lai E AU - Han B AU - Zhang T PY - 2026 JO - Pharmacological research DO - 10.1016/j.phrs.2026.108471 UR - https://doi.org/10.1016/j.phrs.2026.108471 ER -
APA
M, Z., J, H., W, W., E, L., B, H., & T, Z. (2026). Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers.. Pharmacological research. https://doi.org/10.1016/j.phrs.2026.108471
Source records
- pubmed · retrieved 2026-09-25T19:06:55.229Z